High Response Rate to Pegylated Interferon Alpha and Ribavirin Combination Therapy in Hemophilic Children with

Leila Mehrnoush1,2, Seyed-Moayed Alavian1,2, Heidar Sharafi1,2,3

  • 1a Iran Hepatitis Network , Tehran , IR Iran.

Insights

Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) combination therapy shows higher efficacy in hemophilic children with chronic hepatitis C than in adults. This treatment achieved a significantly higher sustained virological response (SVR) rate in pediatric patients.

Area of Science:

  • Hepatology
  • Pediatric Hematology
  • Virology

Background:

  • Chronic hepatitis C (HCV) infection poses a significant health challenge, particularly in hemophilic patients who may have received contaminated blood products.
  • Limited data exists on the effectiveness of Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) combination therapy for HCV in pediatric hemophilic populations.

Purpose of the Study:

  • To assess the efficacy of Peg-IFN and RBV combination therapy in hemophilic children with chronic hepatitis C.
  • To compare treatment outcomes in pediatric hemophilic patients with those in adult hemophilic patients.

Main Methods:

  • A case-control study involving 31 treatment-naive pediatric hemophilic patients (under 16 years) and 62 treatment-naive adult hemophilic patients with HCV genotypes 1 or 3.
  • Patients were matched based on HCV genotype, viral load, and rs12979860 polymorphism.
  • Both groups received Peg-IFN and RBV for 24-48 weeks.

Main Results:

  • Sustained virological response (SVR) was achieved in 83.9% of pediatric patients compared to 62.9% of adult patients (P=0.05).
  • Early virological response was a significant predictor of SVR in both age groups.
  • No significant difference in SVR rates was observed based on HCV genotype, viral load, or rs12979860 polymorphism.

Conclusions:

  • Peg-IFN and RBV combination therapy demonstrates superior efficacy in achieving SVR in hemophilic children compared to adult hemophilic patients with chronic hepatitis C.
  • The findings support the use of this therapeutic regimen in pediatric hemophilic populations, with early virological response as a key indicator of successful treatment.